Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$6.99
+1.2%
$7.70
$6.61
$18.62
$412.93M-0.08429,162 shs741,007 shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$10.35
+16.9%
$8.03
$4.58
$10.39
$518.19M1.62564,492 shs1.06 million shs
Erasca, Inc. stock logo
ERAS
Erasca
$1.61
+8.8%
$1.51
$1.01
$3.31
$456.71M1.08884,545 shs2.98 million shs
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$2.00
+3.1%
$1.59
$0.99
$5.10
$126.41M1.63850,593 shs2.80 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
0.00%-7.29%-0.57%-23.02%-62.58%
CryoPort, Inc. stock logo
CYRX
CryoPort
0.00%+16.82%+26.22%+47.86%+20.91%
Erasca, Inc. stock logo
ERAS
Erasca
0.00%+2.55%+10.27%+0.63%-42.29%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
0.00%+12.99%+24.22%+12.36%-39.76%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$6.99
+1.2%
$7.70
$6.61
$18.62
$412.93M-0.08429,162 shs741,007 shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$10.35
+16.9%
$8.03
$4.58
$10.39
$518.19M1.62564,492 shs1.06 million shs
Erasca, Inc. stock logo
ERAS
Erasca
$1.61
+8.8%
$1.51
$1.01
$3.31
$456.71M1.08884,545 shs2.98 million shs
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$2.00
+3.1%
$1.59
$0.99
$5.10
$126.41M1.63850,593 shs2.80 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
0.00%-7.29%-0.57%-23.02%-62.58%
CryoPort, Inc. stock logo
CYRX
CryoPort
0.00%+16.82%+26.22%+47.86%+20.91%
Erasca, Inc. stock logo
ERAS
Erasca
0.00%+2.55%+10.27%+0.63%-42.29%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
0.00%+12.99%+24.22%+12.36%-39.76%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3.00
Buy$26.80283.40% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
3.00
Buy$12.0015.94% Upside
Erasca, Inc. stock logo
ERAS
Erasca
2.57
Moderate Buy$3.71130.70% Upside
MacroGenics, Inc. stock logo
MGNX
MacroGenics
2.57
Moderate Buy$3.6080.00% Upside

Current Analyst Ratings Breakdown

Latest MGNX, CGEM, ERAS, and CYRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2025
Erasca, Inc. stock logo
ERAS
Erasca
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuyUnderperform$4.00 ➝ $1.00
8/21/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$24.00
8/18/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$35.00 ➝ $28.00
8/18/2025
Erasca, Inc. stock logo
ERAS
Erasca
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweightEqual Weight$4.00 ➝ $2.00
8/15/2025
MacroGenics, Inc. stock logo
MGNX
MacroGenics
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$8.00 ➝ $5.00
8/6/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
8/6/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSector WeightOverweight$15.00
8/6/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeMarket PerformOutperform$16.00
7/22/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$13.00
7/7/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$13.00 ➝ $10.00
6/11/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$22.00
(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/A$10.14 per shareN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M2.27N/AN/A$7.44 per share1.39
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/A$1.50 per shareN/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$149.96M0.84N/AN/A$1.85 per share1.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$167.38M-$3.23N/AN/AN/AN/A-36.56%-34.82%11/6/2025 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M$1.337.78N/AN/A37.21%-9.79%-5.42%11/6/2025 (Estimated)
Erasca, Inc. stock logo
ERAS
Erasca
-$161.65M-$0.45N/AN/AN/AN/A-31.19%-26.34%11/11/2025 (Estimated)
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$66.97M-$0.57N/AN/AN/A-21.99%-40.24%-14.62%11/4/2025 (Estimated)

Latest MGNX, CGEM, ERAS, and CYRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$0.59-$0.57+$0.02-$0.57$28.06 million$22.24 million
8/12/2025Q2 2025
Erasca, Inc. stock logo
ERAS
Erasca
-$0.12-$0.12N/A-$0.12N/AN/A
8/7/2025Q2 2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$0.83-$1.07-$0.24-$1.07N/AN/A
8/5/2025Q2 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20-$0.29-$0.09$2.05$41.74 million$45.45 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/AN/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/A
9.83
9.83
CryoPort, Inc. stock logo
CYRX
CryoPort
0.39
16.24
15.47
Erasca, Inc. stock logo
ERAS
Erasca
N/A
11.03
11.04
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/A
5.26
5.02

Institutional Ownership

CompanyInstitutional Ownership
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
86.31%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Erasca, Inc. stock logo
ERAS
Erasca
67.78%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
96.89%

Insider Ownership

CompanyInsider Ownership
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
6.07%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.10%
Erasca, Inc. stock logo
ERAS
Erasca
14.40%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
13.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3059.07 million55.49 millionOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.07 million45.01 millionOptionable
Erasca, Inc. stock logo
ERAS
Erasca
120283.67 million242.82 millionOptionable
MacroGenics, Inc. stock logo
MGNX
MacroGenics
43063.21 million54.99 millionOptionable

Recent News About These Companies

William Heiden Bought 909% More Shares In MacroGenics
William Heiden Bought 909% More Shares In MacroGenics
Stifel Nicolaus Keeps Their Hold Rating on MacroGenics (MGNX)
Citizens JMP Keeps Their Hold Rating on MacroGenics (MGNX)
MacroGenics Revenue Doubles in Q2
MacroGenics: Q2 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cullinan Therapeutics stock logo

Cullinan Therapeutics NASDAQ:CGEM

$6.99 +0.08 (+1.16%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$7.13 +0.14 (+2.02%)
As of 09/5/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$10.35 +1.50 (+16.95%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$10.10 -0.24 (-2.37%)
As of 09/5/2025 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Erasca stock logo

Erasca NASDAQ:ERAS

$1.61 +0.13 (+8.78%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$1.56 -0.05 (-3.11%)
As of 09/5/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

MacroGenics stock logo

MacroGenics NASDAQ:MGNX

$2.00 +0.06 (+3.09%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$2.00 +0.00 (+0.25%)
As of 09/5/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.